Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Shortage Looming Large, Cipla Offers Generic Tamiflu, Relenza To U.S. Health Department

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Known for supplying low-priced anti-retroviral cocktail therapy to frontline African nations to combat the spread of HIV/AIDS, Cipla - India's largest drug maker by market share - is in discussions with U.S. health agencies to boost production of antiviral oseltamivir, the generic for Roche's Tamiflu for treating the rapidly spreading H1N1 virus

You may also be interested in...



New Avian Flu Outbreak In China Sparks Scramble For Flu Drugs And Vaccines In Asia

Roche, GSK could benefit from influenza drug stockpiling in Asia as H7N9 strain of avian flu hits headlines, despite public health official calls of overreaction.

Complex Regulatory Pathways Pose Hurdles For Effective CLs; Cipla’s Hamied Calls For Automatic Licensing Rights

Cipla Chairman Yusuf Hamied has proposed an automatic licensing mechanism that could avoid the need for a compulsory license and would allow generic firms to launch patented drugs via an automatic route.

As H1N1 Virus Spreads Fast In India, Government Ups Its Offensive

MUMBAI - India's health ministry has gone into hyperactive mode to combat the spread of the A/H1N1 influenza virus. The disease has claimed 14 lives over the last five days, while close to 1,000 more people tested positive and were treated in government-run hospitals

Related Content

UsernamePublicRestriction

Register

SC070295

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel